$JNJ  Analyst Commentary Credit Suisse Strong April and May Trends in IMS Sales and Scrips Point to Upside for Q2 U.S. Pharma Reiterates at an Outperform Rating $161 PT Forward Earnings Estimates 12/22   $9.95